OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 100,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the acquisition, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were bought at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Down 1.9 %

NASDAQ:OPK traded down $0.03 on Friday, reaching $1.59. 1,485,415 shares of the company’s stock were exchanged, compared to its average volume of 6,940,523. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a fifty day simple moving average of $1.51 and a 200-day simple moving average of $1.43. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.75.

Analyst Upgrades and Downgrades

A number of analysts recently commented on OPK shares. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research report on Saturday, July 27th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Asset Management Inc grew its stake in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of OPKO Health during the 1st quarter valued at $26,000. FMR LLC increased its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Algert Global LLC purchased a new stake in shares of OPKO Health in the second quarter worth $44,000. Finally, Headlands Technologies LLC purchased a new position in OPKO Health during the first quarter worth about $47,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.